A 2025 study of single-blastocyst transfers found no increase in birth defects or adverse pregnancy outcomes when transferring poor quality embryos compared to good quality ones.
Neonatal outcomes
The ASRM has released their 2024 committee opinion on the use of PGT-A, covering the use of PGT-A for patients with a good prognosis, advanced age, donor eggs, recurrent pregnancy loss and more.
Researchers in a 2024 study found no health problems in children born from mosaic embryo transfers, with an average age of 3 years. They also found no differences in obstetric outcomes between mosaic and euploid transfers.
